It remains to be seen whether PARP inhibitors will be active in high-grade serous carcinomas with either BRCA1 epigenetic silencing or no evidence of BRCA1 loss, although it is conceivable that such cells may lack homologous repair functions. This evidence concerns the gene PARP1 and serous adenocarcinoma.